Understanding how cell differences affect drug therapy
Systems Pharmacology for overcoming cell variability
This study is looking at how different types of cells in the body respond to treatments, with the goal of finding better, personalized therapies for people with complex conditions like optic nerve injuries, so that patients can have more effective recovery options tailored just for them.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Icahn School of Medicine at Mount Sinai NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-10656377 on NIH RePORTER |
What this research studies
This research investigates the variability among different cell types and how these differences can impact the effectiveness of drug therapies for complex diseases. By utilizing advanced techniques like single cell RNA sequencing, the study aims to identify various subtypes of cells and their unique responses to treatments. The approach combines computational modeling with experimental data to develop targeted combination therapies that could improve recovery from conditions such as optic nerve injuries. Patients may benefit from more personalized and effective treatment options based on their specific cellular profiles.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults over 21 years old who are experiencing complex diseases that may benefit from combination drug therapies.
Not a fit: Patients with conditions that do not involve cellular variability or those who are under 21 years old may not receive benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective drug therapies tailored to individual cellular responses, improving treatment outcomes for patients with complex diseases.
How similar studies have performed: Other research has shown promise in using systems pharmacology approaches to improve drug therapies, indicating that this method could be a valuable advancement in treatment strategies.
Where this research is happening
New York, United States
- Icahn School of Medicine at Mount Sinai — New York, United States (Active)
Researchers
- Principal investigator: Iyengar, Srinivas Ravi V — Icahn School of Medicine at Mount Sinai
- Study coordinator: Iyengar, Srinivas Ravi V
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.